Bringing clarity
to the world of
duplicate discounts

The 340B Program aims to help covered entities reach more eligible patients while providing more comprehensive services. This goal is a noble one that all stakeholders can support – but is it working as intended?

Through a thorough analysis of more than 300,000 claims reviewed by more than 2,100 covered entities, a clearer picture of the issue of duplicate and non-compliant MDRP and 340B Program discounts and their magnitude is beginning to emerge. More importantly, this analysis highlights a path forward to bring transparency and integrity to two critical federal drug discount programs.

Kalderos, Inc. © 2019 All rights reserved